Single-Ascending Dose Study of AMG 333 in Healthy Subjects and Subjects With Migraines
Status:
Completed
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to determine whether AMG 333 is safe and well tolerated
in healthy subjects and subjects with migraines. As part of the secondary objectives, this
study will characterize the pharmacokinetic (PK) profile of AMG 333, as well as characterize
the effect of AMG 333 on the cold pressor test (CPT)-induced increase in blood pressure after
single oral doses in healthy subjects and subjects with migraines